Biotech RadarJobs updated

COMPANY

Treeline Biosciences, Inc.

HQ: Watertown, MA source · treeline.bio ↗

Clinical Phase 1

Location: Watertown, MA · source · Sep 4, 2025

Profile checked Oct 10, 2026

Keywords: Lymphoma Small Cell Lung Cancer Neuroendocrine Cancer Malignant Pleural Mesotheliomas Synovial Sarcomas Non Hodgkin Lymphoma KRAS Mutant Solid Tumors TLN-121 TLN-254 TLN-499 TLN-372

4Trials (company is sponsor)

Timeline

  1. Trial start Phase 1: TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid Tumors source ↗
  2. Trial start Phase 1: TLN-372 in Advanced KRAS Mutant Solid Tumors source ↗
  3. Trial start Phase 1: TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas source ↗
  4. Trial start Phase 1: A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT07713732TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid TumorsPhase 1RecruitingAug 5, 2026Aug 29, 2030 (estimated)
NCT07082803TLN-121 in Relapsed or Refractory Non-Hodgkin LymphomasPhase 1RecruitingJun 23, 20252030-09 (estimated)
NCT06733441A Study of TLN-254 in Participants With Relapsed or Refractory T-cell LymphomaPhase 1Active, not recruitingDec 16, 2024Nov 15, 2026 (estimated)
NCT07204340TLN-372 in Advanced KRAS Mutant Solid TumorsPhase 1RecruitingSep 29, 2025Dec 3, 2031 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback